Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Recurrent copy number alterations in young women with breast cancer.

Chi C, Murphy LC, Hu P.

Oncotarget. 2018 Jan 29;9(14):11541-11558. doi: 10.18632/oncotarget.24336. eCollection 2018 Feb 20.

2.

Breast Cancers Activate Stromal Fibroblast-Induced Suppression of Progenitors in Adjacent Normal Tissue.

Chatterjee S, Basak P, Buchel E, Safneck J, Murphy LC, Mowat M, Kung SK, Eirew P, Eaves CJ, Raouf A.

Stem Cell Reports. 2018 Jan 9;10(1):196-211. doi: 10.1016/j.stemcr.2017.11.002. Epub 2017 Dec 7.

3.

Regulation of mitochondrial dynamics by DISC1, a putative risk factor for major mental illness.

Murphy LC, Millar JK.

Schizophr Res. 2017 Sep;187:55-61. doi: 10.1016/j.schres.2016.12.027. Epub 2017 Jan 9. Review.

PMID:
28082141
4.

Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.

Wang J, Duan Z, Nugent Z, Zou JX, Borowsky AD, Zhang Y, Tepper CG, Li JJ, Fiehn O, Xu J, Kung HJ, Murphy LC, Chen HW.

Cancer Lett. 2016 Aug 10;378(2):69-79. doi: 10.1016/j.canlet.2016.05.004. Epub 2016 May 6.

PMID:
27164560
5.

Using intervention mapping to develop a theory-driven, group-based complex intervention to support self-management of osteoarthritis and low back pain (SOLAS).

Hurley DA, Murphy LC, Hayes D, Hall AM, Toomey E, McDonough SM, Lonsdale C, Walsh NE, Guerin S, Matthews J.

Implement Sci. 2016 Apr 26;11:56. doi: 10.1186/s13012-016-0418-2. Review.

6.

NDE1 and GSK3β Associate with TRAK1 and Regulate Axonal Mitochondrial Motility: Identification of Cyclic AMP as a Novel Modulator of Axonal Mitochondrial Trafficking.

Ogawa F, Murphy LC, Malavasi EL, O'Sullivan ST, Torrance HS, Porteous DJ, Millar JK.

ACS Chem Neurosci. 2016 May 18;7(5):553-64. doi: 10.1021/acschemneuro.5b00255. Epub 2016 Feb 16.

PMID:
26815013
7.
8.

The steroid receptor RNA activator protein (SRAP) controls cancer cell migration/motility.

Yan Y, Cooper C, Hamedani MK, Guppy B, Xu W, Tsuyuki D, Zhang C, Nugent Z, Blanchard A, Davie JR, McManus K, Murphy LC, Myal Y, Leygue E.

FEBS Lett. 2015 Dec 21;589(24 Pt B):4010-8. doi: 10.1016/j.febslet.2015.11.007. Epub 2015 Nov 17.

9.

Estrogen regulates luminal progenitor cell differentiation through H19 gene expression.

Basak P, Chatterjee S, Weger S, Bruce MC, Murphy LC, Raouf A.

Endocr Relat Cancer. 2015 Aug;22(4):505-17. doi: 10.1530/ERC-15-0105. Epub 2015 May 5.

10.

Intratumoural inflammation and endocrine resistance in breast cancer.

Murray JI, West NR, Murphy LC, Watson PH.

Endocr Relat Cancer. 2015 Feb;22(1):R51-67. doi: 10.1530/ERC-14-0096. Epub 2014 Nov 17. Review.

11.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8.

12.

The kinome associated with estrogen receptor-positive status in human breast cancer.

Bruce MC, McAllister D, Murphy LC.

Endocr Relat Cancer. 2014 Oct;21(5):R357-70. doi: 10.1530/ERC-14-0232. Epub 2014 Jul 23. Review.

13.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Aug;146(3):657-67. doi: 10.1007/s10549-014-3050-3. Epub 2014 Jul 10.

PMID:
25007965
14.

Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy.

Ruddy SC, Lau R, Cabrita MA, McGregor C, McKay BC, Murphy LC, Wright JS, Durst T, Pratt MA.

Mol Cancer Ther. 2014 Jul;13(7):1882-93. doi: 10.1158/1535-7163.MCT-13-1066. Epub 2014 Apr 30.

15.

The path of screw insertion for stabilization of the scapholunate joint: a cadaveric study.

Flannery OM, Murphy LC, Dockery P, O'Sullivan ME.

Hand Surg. 2014;19(1):145-9. doi: 10.1142/S0218810414970028.

PMID:
24641760
16.

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.

Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1637-47. doi: 10.1007/s00432-013-1485-2. Epub 2013 Aug 2.

PMID:
23907597
17.

Claudin 1 expression in basal-like breast cancer is related to patient age.

Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y.

BMC Cancer. 2013 May 30;13:268. doi: 10.1186/1471-2407-13-268.

18.

Candida cerebral abscesses: a case report and review of the literature.

Fennelly AM, Slenker AK, Murphy LC, Moussouttas M, DeSimone JA.

Med Mycol. 2013 Oct;51(7):779-84. doi: 10.3109/13693786.2013.789566. Epub 2013 May 8. Review.

PMID:
23651179
19.

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).

Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC.

Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11.

PMID:
23579816
20.

A bi-faceted role of estrogen receptor β in breast cancer.

Leygue E, Murphy LC.

Endocr Relat Cancer. 2013 May 30;20(3):R127-39. doi: 10.1530/ERC-12-0389. Print 2013 Jun. Review.

21.

The path of screw insertion for stabilization of the scapholunate joint. A radiological study.

Murphy LC, Flannery OM, O'Sullivan ME.

J Hand Surg Eur Vol. 2013 Jun;38(5):558-9. doi: 10.1177/1753193412460811. Epub 2012 Sep 17. No abstract available.

PMID:
22988023
22.

Variation in the autism candidate gene GABRB3 modulates tactile sensitivity in typically developing children.

Tavassoli T, Auyeung B, Murphy LC, Baron-Cohen S, Chakrabarti B.

Mol Autism. 2012 Jul 6;3(1):6. doi: 10.1186/2040-2392-3-6.

23.

The role of estrogen receptor-β in breast cancer.

Murphy LC, Leygue E.

Semin Reprod Med. 2012 Jan;30(1):5-13. doi: 10.1055/s-0031-1299592. Epub 2012 Jan 23. Review.

PMID:
22271289
24.

Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.

West NR, Murphy LC, Watson PH.

Endocr Relat Cancer. 2012 Apr 10;19(2):181-95. doi: 10.1530/ERC-11-0326. Print 2012 Apr.

25.

Clinical significance of estrogen receptor phosphorylation.

Murphy LC, Seekallu SV, Watson PH.

Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14. doi: 10.1677/ERC-10-0070. Print 2011 Feb. Review.

27.

A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.

Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC.

Endocr Relat Cancer. 2010 Jun 3;17(3):589-97. doi: 10.1677/ERC-10-0030. Print 2010 Sep.

28.

Targeted production of proprotein convertase PC1 enhances mammary development and tumorigenesis in transgenic mice.

Blanchard A, Iwasiow B, Yarmill A, Fresnosa A, Silha J, Myal Y, Murphy LC, Chrétien M, Seidah N, Shiu RP.

Can J Physiol Pharmacol. 2009 Oct;87(10):831-8. doi: 10.1139/Y09-073.

PMID:
20052009
29.

Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen.

Skliris GP, Nugent Z, Watson PH, Murphy LC.

Horm Cancer. 2010 Aug;1(4):215-21. doi: 10.1007/s12672-010-0049-z.

PMID:
21761367
30.

Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E.

Breast Cancer Res. 2009;11(5):R67. doi: 10.1186/bcr2359.

31.

Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Cooper C, Guo J, Yan Y, Chooniedass-Kothari S, Hube F, Hamedani MK, Murphy LC, Myal Y, Leygue E.

Nucleic Acids Res. 2009 Jul;37(13):4518-31. doi: 10.1093/nar/gkp441. Epub 2009 May 29.

32.

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo.

Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M, Watson PH.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):90-5. doi: 10.1016/j.jsbmb.2009.01.017. Epub 2009 Feb 6. Review.

PMID:
19429437
33.

Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.

Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y.

Virchows Arch. 2009 Jun;454(6):647-56. doi: 10.1007/s00428-009-0770-6. Epub 2009 Apr 23.

PMID:
19387682
34.

Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas.

Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC.

Breast Cancer Res Treat. 2009 Dec;118(3):443-53. doi: 10.1007/s10549-008-0267-z. Epub 2008 Dec 23.

35.

Influence of evolution in tumor biobanking on the interpretation of translational research.

Barnes RO, Parisien M, Murphy LC, Watson PH.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3344-50. doi: 10.1158/1055-9965.EPI-08-0622.

36.

Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.

Weitsman GE, Weebadda W, Ung K, Murphy LC.

Breast Cancer Res Treat. 2009 Nov;118(2):269-79. doi: 10.1007/s10549-008-0221-0. Epub 2008 Oct 21.

PMID:
18941890
37.

Role of wild-type estrogen receptor-beta in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells.

Flynn JM, Dimitrijevich SD, Younes M, Skliris G, Murphy LC, Cammarata PR.

Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E637-47. doi: 10.1152/ajpendo.90407.2008. Epub 2008 Jun 24.

38.

Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers.

Skliris GP, Hubé F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y.

Histopathology. 2008 Feb;52(3):355-69. doi: 10.1111/j.1365-2559.2007.02955.x.

39.

Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.

Skliris GP, Leygue E, Watson PH, Murphy LC.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):1-10. doi: 10.1016/j.jsbmb.2007.12.010. Epub 2007 Dec 8. Review.

PMID:
18243688
40.

Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors.

Cherlet T, Murphy LC.

Mol Cell Biochem. 2007 Dec;306(1-2):33-42. Epub 2007 Jul 28.

PMID:
17660955
41.

S100A7 (psoriasin) influences immune response genes in human breast cancer.

Mandal S, Curtis L, Pind M, Murphy LC, Watson PH.

Exp Cell Res. 2007 Aug 15;313(14):3016-25. Epub 2007 Mar 30.

PMID:
17560571
42.

Targeting the EGFR pathway for cancer therapy.

Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M.

Curr Med Chem. 2006;13(29):3483-92. Review.

PMID:
17168718
43.

Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo.

Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, Tomes L, Watson PH.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):139-46. Epub 2006 Nov 7. Review.

PMID:
17092701
44.

Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression.

Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC.

Cancer Res. 2006 Oct 15;66(20):10162-70.

45.

Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer.

Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, Davie JR, Shiu RP, Watson PH, Murphy LC.

Breast Cancer Res Treat. 2007 Jul;104(1):75-85. Epub 2006 Sep 29.

PMID:
17009105
46.

Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.

Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC.

Br J Cancer. 2006 Sep 4;95(5):616-26. Epub 2006 Aug 1.

47.

The Prohibitins: emerging roles in diverse functions.

Mishra S, Murphy LC, Murphy LJ.

J Cell Mol Med. 2006 Apr-Jun;10(2):353-63. Review.

48.

Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?

Murphy LC, Watson PH.

Endocr Relat Cancer. 2006 Jun;13(2):327-34. Review.

49.

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC.

Breast Cancer Res Treat. 2006 Nov;100(1):23-31. Epub 2006 May 17.

PMID:
16705367
50.

Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally transformed and normal cultured human lens epithelial cells.

Cammarata PR, Flynn J, Gottipati S, Chu S, Dimitrijevich S, Younes M, Skliris G, Murphy LC.

Exp Eye Res. 2005 Aug;81(2):165-75.

PMID:
16080910

Supplemental Content

Loading ...
Support Center